GSK plc
CIK 1131399 · last filed 2025-12-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
THRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
LONDON WC1A 1DG
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WVE | 10%+ Owner | 18,245,691 | $3.33 | $60.67M | $66.77M | 3 | 2025-12-15 |
| Theravance Biopharma, Inc. (TBPH) Delisted | 10%+ Owner | 0 | $17.03 | $0 | $29986.81B | 4 | 2022-09-20 |
| CVRX | 10%+ Owner | 33,316 | $1.44 | $48.0K | $4.95M | 1 | 2021-07-06 |
| LYEL | 10%+ Owner | 1,512,659 | $9.34 | $14.13M | $0 | 1 | 2021-06-23 |
| INVA | 10%+ Owner | 0 | $20.96 | $0 | -$392.06M | 1 | 2021-05-24 |
| Decibel Therapeutics, Inc. (DBTX) Delisted | Director | 1,183,663 | $4.91 | $5.81M | $2.70M | 1 | 2021-02-19 |
| BCYC | Director | 1,910,531 | $3.65 | $6.97M | $5.31M | 2 | 2020-09-18 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 4,626,389 | $0.00 | $2.8K | $11.06M | 3 | 2020-07-30 |
| Pandion Therapeutics, Inc. (PAND) Delisted | Director | 1,538,724 | $60.05 | $92.40M | $6.50M | 1 | 2020-07-22 |
| NKTX | Director | 604,589 | $1.79 | $1.08M | $15.00M | 1 | 2020-07-16 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 2,253,660 | $76.01 | $171.30M | $18.85M | 3 | 2020-05-26 |
| PGNY | 10%+ Owner | 6,238,244 | $28.20 | $175.95M | -$103.00M | 2 | 2020-05-21 |
| Principia Biopharma Inc. (PRNB) Delisted | 10%+ Owner | 2,982,855 | — | — | $14.59M | 4 | 2019-10-22 |
| FULC | 10%+ Owner | 1,785,714 | $3.65 | $6.52M | $0 | 1 | 2019-07-24 |
| Morphic Holding, Inc. (MORF) Delisted | Director | 2,633,772 | $56.99 | $150.10M | $5.00M | 1 | 2019-07-02 |
| CCXI | 10%+ Owner | 0 | $10.24 | $0 | -$85.85M | 2 | 2018-10-18 |
| SPRO | 10%+ Owner | 1,934,006 | $1.06 | $2.05M | $7.00M | 2 | 2018-07-17 |
| Translate Bio, Inc. (TBIO) Delisted | 10%+ Owner | 165,230 | $0.00 | $17 | $3.50M | 1 | 2018-07-03 |
| HTG MOLECULAR DIAGNOSTICS, INC (HTGM) Delisted | 10%+ Owner | 4,404 | $0.48 | $2.1K | -$978.9K | 3 | 2017-03-30 |
| CRISPR Therapeutics AG (PZRX) Delisted | 10%+ Owner | 3,154,127 | — | — | $931.0K | 2 | 2016-10-26 |
| Innoviva, Inc. (THRX) Delisted | 10%+ Owner | 32,005,260 | $4.06 | $129.94M | $363597.22B | 20 | 2015-08-07 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | 10%+ Owner | 1,436,448 | $0.39 | $565.4K | -$12.13M | 2 | 2015-02-24 |
| AMICUS THERAPEUTICS, INC. (FOLD) Delisted | 10%+ Owner | 0 | $14.49 | $0 | -$38.29M | 3 | 2014-10-28 |
| PATH | 0 | $14.12 | $0 | $0 | 1 | 2014-02-24 | |
| CONCERT PHARMACEUTICALS, INC. (CNCE) Delisted | 1,356,533 | $8.37 | $11.35M | $490.0K | 1 | 2014-02-20 | |
| HUMAN GENOME SCIENCES INC (HGSI) Delisted | Director | 171,070,522 | — | — | $1.07B | 2 | 2012-08-03 |
| DGX | Director | 15,377,551 | $242.09 | $3.72B | -$1.95B | 4 | 2011-02-02 |
| Anacor Pharmaceuticals, Inc. (ANAC) Delisted | 10%+ Owner | 2,771,374 | $10.19 | $28.24M | $5.00M | 1 | 2010-11-24 |
| Redpoint Bio CORP (BDSI) Delisted | 10%+ Owner | — | $5.59 | — | $0 | 1 | 2010-03-16 |
| EPIX Pharmaceuticals, Inc. (EPIX) Delisted | 10%+ Owner | 227,962 | $0.20 | $45.9K | $0 | 1 | 2007-12-20 |
Recent Filings · Page 7 of 8
78 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2012-07-17 | AMICUS THERAPEUTICS, INC. (FOLD) Delisted | Buy (P) | +2,949,581 | $18.58M | EDGAR |
| 2012-05-16 | Innoviva, Inc. (THRX) Delisted | Buy (P) | +10,000,000 | $212.89M | EDGAR |
| 2012-02-15 | CCXI | Conv (C) | +6,643,492 | $0 | EDGAR |
| 2012-02-14 | Innoviva, Inc. (THRX) Delisted | Buy (P) | +88,468 | $1.60M | EDGAR |
| 2011-11-03 | Innoviva, Inc. (THRX) Delisted | Buy (P) | +58,411 | $1.30M | EDGAR |
| 2011-08-03 | Innoviva, Inc. (THRX) Delisted | Buy (P) | +102,466 | $2.02M | EDGAR |
| 2011-07-25 | Innoviva, Inc. (THRX) Delisted | Conv (C) | +9,401,499 | $0 | EDGAR |
| 2011-05-04 | Innoviva, Inc. (THRX) Delisted | Buy (P) | +261,299 | $6.69M | EDGAR |
| 2011-02-22 | Innoviva, Inc. (THRX) Delisted | Buy (P) | +152,278 | $3.61M | EDGAR |
| 2011-02-02 | DGX | Sell (S) | −30,755,151 | -$1.69B | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.